GenMark Diagnostics is a provider of automated, multiplex molecular diagnostic testing systems. The Company develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.  It offers four Food and Drug Administration -cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. GenMark also offers a Hepatitis C genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only. 

Type
Public
HQ
Carlsbad, US
Founded
2010
Size (employees)
308 (est)
GenMark Diagnostics was founded in 2010 and is headquartered in Carlsbad, US
Report incorrect company information

Key People/Management at GenMark Diagnostics

Hany Massarany

Hany Massarany

President and Chief Executive Officer
Scott Mendel

Scott Mendel

Chief Financial Officer
Jon Kayyem

Jon Kayyem

Founder and Senior Vice President, Research and Development
Michael Gleeson

Michael Gleeson

Senior Vice President, North American Commercial Operations
James McNally

James McNally

Senior Vice President, Marketing and Business Development
Brian Mitchell

Brian Mitchell

Senior Vice President, Operations
Eric Stier

Eric Stier

Senior Vice President, General Counsel and Secretary
Jennifer Williams

Jennifer Williams

Senior Vice President, Human Resources

GenMark Diagnostics Office Locations

GenMark Diagnostics has an office in Edinburgh, San Diego, Englewood, Syracuse and in 32 other locations
Carlsbad, US (HQ)
5964 La Pl Ct
Zug, CH
6 General-Guisan-Strasse
Show all (36)
Report incorrect company information

GenMark Diagnostics Financials and Metrics

GenMark Diagnostics Financials

GenMark Diagnostics's revenue was reported to be $49.27 m in FY, 2016 which is a 25% increase from the previous period.
USD

Revenue (Q2, 2017)

12.4 m

Gross profit (Q2, 2017)

4.9 m

Gross profit margin (Q2, 2017), %

39.5%

Net income (Q2, 2017)

(18 m)

EBIT (Q2, 2017)

(17.3 m)

Market capitalization (5-Feb-2018)

245.7 m

Cash (3-Feb-2018)

88.4 m
GenMark Diagnostics's current market capitalization is $245.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

27.4 m30.6 m39.4 m49.3 m

Revenue growth, %

12%29%25%

Cost of goods sold

15.3 m19.7 m

Gross profit

24.1 m29.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

4.6 m7.9 m6.6 m6.3 m10.1 m7.6 m8.5 m11.1 b12.5 m10.8 m12.5 b12.4 m

Cost of goods sold

4.1 m3.7 m3.2 m2.7 m4 m3.3 m3.4 m4.4 b4.7 m4.4 m6.4 b7.5 m

Gross profit

499 k4.2 m3.4 m3.6 m6.1 m4.4 m5.1 m6.7 b7.8 m6.5 m6.2 b4.9 m

Gross profit Margin, %

11%53%51%57%61%57%60%60%62%60%49%40%
Annual
usdY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

16.5 m51.3 m25.3 m51.3 m35.7 m36.9 m35.4 m16 m

Accounts Receivable

Inventories

2.1 m2.1 m3.1 m3.1 m

Current Assets

111.1 m78.1 m56 m58.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

63.3 m27.9 m26.8 m25.7 m36.9 m32.1 m34.2 m27.9 m29.6 m19.3 m13.2 m88.4 m

Inventories

2 m1.8 m1.2 m1.5 m2.1 m2 m2.7 m2.4 m2.6 m4.2 m9 m7.1 m

Current Assets

117.5 m102.6 m93.8 m84.7 m78.3 m69.1 m62.1 m46.5 m46.8 m64.7 m42.1 m122.2 m

PP&E

7.9 m9.6 m9.9 m10.2 m11.4 m11.8 m11.6 m11.7 m12.7 m17.3 m18.5 m19.8 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(33.6 m)(38.3 m)(42.2 m)(50.6 m)

Depreciation and Amortization

2.5 m2.7 m3.4 m3.9 m

Inventories

(1.3 m)(229 k)(3.5 m)(3.5 m)

Accounts Payable

1.3 m85 k4.1 m4.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Net Income

(10.8 m)(8.8 m)(11.2 m)(9.7 m)(9.9 m)
USDY, 2017

Financial Leverage

1.6 x
Show all financial metrics

GenMark Diagnostics Operating Metrics

FY, 2014FY, 2015FY, 2016

Patents Issued

130 120 100

Patents Pending

25 35 30
Show all operating metrics
Report incorrect company information